An Open-label Study to Evaluate the Effect of Single Dose GS-6615 on QT, Safety and Tolerability in Subjects With Long QT-3 Syndrome

Trial Profile

An Open-label Study to Evaluate the Effect of Single Dose GS-6615 on QT, Safety and Tolerability in Subjects With Long QT-3 Syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Eleclazine (Primary)
  • Indications Long QT syndrome
  • Focus Pharmacodynamics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 16 Nov 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 01 Aug 2014 The treatment arms have been changed from 5 to 6 along with changes in endpoints and inclusion/ exclusion criteria, according to ClinicalTrials.gov record.
    • 01 Aug 2014 Planned number of patients changed from 25 to 34 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top